Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 10 | History Defined

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

Tribune News Service

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

Benzinga

What's In The Offing For Infosys (INFY) This Earnings Season?

Infosys Limited (NYSE: INFY) is scheduled to report first-quarter fiscal 2023 results on Jul 24. Over the trailing four quarters, the India-based IT services provider's earnings beat the Zacks Consensus Estimate once, met the same on two occasions and missed it once, the average beat being 0.2%.

Benzinga

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.

Benzinga

Pharma giant Merck nearing possible $40 billion acquisition of Washington-based Seagen

Bothell-based Seagen may be acquired by pharma giant Merck in a deal valued at $40 billion, The Wall Street Journal reported Wednesday.

Tribune News Service

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

StockNews.com

Merck Discussing Another Drugmaker Buyout -- Buy Or Sell?

Merck & Co., Inc. (MRK) reported solid first-quarter results beating analysts’ estimates for sales and earnings. In addition, given that the company is in talks to acquire another biotech firm to boost its cancer-drug portfolio, would it be wise to buy the stock now? Let’s discuss.

Benzinga

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Benzinga

Merck To Start Pivotal Trial For Next-Gen Pneumococcal Vaccine Next Month

Merck & Co Inc (NYSE:MRK) presented results from the Phase 1/2 study, evaluating V116 in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). Data were shared at the International Symposium on Pneumococci and Pneumococcal Diseases. V116 targets serotypes that account for 85% of…

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga

Merck, Ridgeback Announce New Molnupiravir Data From Late-Stage COVID-19 Study

Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease. A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care…

The Philadelphia Inquirer

Ex-Merck CEO Ken Frazier and his coalition of business leaders plan to hire or promote 1M Black workers

It's called the "bachelor barrier" — the undergraduate degree requirement that many African American and other people of color don't meet, which keeps them from a promotion or a new job.

Benzinga

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and…

Benzinga

Germany's Merck To Launch Semiconductor Base In China

German semiconductor supplier of chemicals and materials Merck KGaA (OTC:MKKGY) forged a contract with local authorities to open a semiconductor base in China's Zhangjiagang, Reuters reports. The new 69-acre base will house production plants for thin-film materials and electronic specialty gasses, warehouses, and operation centers. Previously Merck disclosed plans to invest at least…

1 … 9 10 11 12

Organisations

Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.